



**ASX / Media Release**  
**19 October 2016**

## **Final Director's Interest Notice - Martin Rogers**

**Sydney, Australia, 19 October 2016:** OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) a late stage medical devices company focused on localised treatments for subjects with pancreatic and liver cancer, today announced that Martin Rogers has formally retired as a Director of the Company post the Annual General Meeting held on 18 October 2016. Refer the attached Appendix 3Z Final Director's Interest Notice.

– ENDS –

Company	Investor Enquiries	Media
<b>Mr Daniel Kenny</b> CEO & Managing Director E: <a href="mailto:daniel.kenny@oncosil.com.au">daniel.kenny@oncosil.com.au</a> T: +61 2 9223 3344	<b>David Allen or John Granger</b> Hawkesbury Partners E: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a> T: +61 2 9325 9046	<b>James Moses</b> Mandate Corporate E: <a href="mailto:james@mandatecorporate.com.au">james@mandatecorporate.com.au</a> M: +61 420 991 574

### **About OncoSil**

OncoSil is a clinical-stage medical device company seeking to provide a new medical radiation treatment for cancer subjects. OncoSil's lead product, OncoSil™ is silicon and phosphorus (p32) beta emitter, able to be implanted by an endoscopically placed catheter in localised solid tumours of subjects with pancreatic cancer. Treatment with the OncoSil™ device, known as brachytherapy, is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil has conducted four clinical trials with encouraging results on tolerability, safety and efficacy. A CE Mark application for regulatory approval to commercially sell the OncoSil™ device in the EU and other non-US markets is under review with commercial launch planned for 2H2016, subject to approval. An Investigational Device Exemption has been granted by the United States Food and Drug Administration to conduct a clinical trial of the OncoSil™ device aimed at supporting an FDA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for subjects diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6<sup>th</sup> most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of subjects with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.

## Forward Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

Name of entity: ONCOSIL MEDICAL LIMITED
ABN: 89 113 824 141

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	MARTIN ROGERS
Date of last notice	20/03/2014
Date that director ceased to be director	18/10/2016

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
------------------------------

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
Ordinary shares and options held in the name of director related entities, Rogers SF Management Pty Ltd <Rogers Super Fund A/C> and Structure Investments Pty Ltd <Rogers Family A/C>. Martin Rogers is a member of the Rogers Super Fund	5,312,532 Fully Paid Ordinary Shares 5,000,000 Loan Funded Shares 19,000,000 Unlisted Options

#### Part 3 – Director's interests in contracts

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

---

+ See chapter 19 for defined terms.